Date: 23-Jul-2019

VolitionRx commences lung cancer clinical study with Fosun in China

Belgium based VolitionRx Limited has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. to help introduce the Nu.Q(TM) platform to China. Based on recent promising proof-of-concept data using Volitions product-grade Nu.Q assays, the parties have commenced a clinical study in China in lung cancer. Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, commented: We are happy to have executed this agreement with Fosun Long March and are delighted that the clinical study is already underway and expected to be completed by the end of this year."